IceCure Medical Ltd. (NASDAQ:ICCM) Short Interest Update

IceCure Medical Ltd. (NASDAQ:ICCM) was the recipient of a significant decrease in short interest in the month of June. As of June 15th, there was short interest totaling 89,416 shares, a decrease of 87.6% from the May 31st total of 718,392 shares. Currently, 3.3% of the shares of the company are short sold. Based on an average daily trading volume, of 160,692 shares, the short-interest ratio is presently 0.6 days.

IceCure Medical Stock Performance

Shares of NASDAQ ICCM traded down $1.29 during trading on Friday, hitting $5.73. 536,508 shares of the company traded hands, compared to its average volume of 1,673,341. The business’s fifty day moving average is $6.77 and its 200 day moving average is $13.83. The firm has a market capitalization of $16.09 million, a price-to-earnings ratio of -0.80 and a beta of 0.40. IceCure Medical has a fifty-two week low of $2.12 and a fifty-two week high of $42.00.

IceCure Medical (NASDAQ:ICCM) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.03). IceCure Medical had a negative return on equity of 211.73% and a negative net margin of 441.60%.The company had revenue of $0.91 million during the quarter, compared to analysts’ expectations of $1.34 million. On average, analysts predict that IceCure Medical will post -3.51 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on ICCM. Weiss Ratings reiterated a “sell (e+)” rating on shares of IceCure Medical in a research note on Tuesday, April 21st. Alliance Global Partners started coverage on shares of IceCure Medical in a research report on Monday, May 4th. They set a “buy” rating for the company. Finally, Maxim Group dropped their target price on shares of IceCure Medical from $90.00 to $30.00 and set a “buy” rating for the company in a report on Thursday, May 14th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $62.70.

Key IceCure Medical News

Here are the key news stories impacting IceCure Medical this week:

• Positive Sentiment: IceCure Medical said it has regained compliance with Nasdaq’s minimum bid price requirement, removing a delisting-related overhang that had been hanging over the shares. IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement
• Positive Sentiment: Brookline Capital Markets raised near-term earnings estimates for several periods, including Q2, Q3, Q4, FY2026, FY2027, and FY2028, signaling a somewhat better earnings outlook than before. Icecure Medical Earnings Estimates, EPS & Revenue | NASDAQ:ICCM
• Neutral Sentiment: Short interest fell sharply in June to 89,416 shares, which may reduce bearish pressure, but the company remains a thinly traded microcap and sentiment can still swing quickly.
• Negative Sentiment: Analysts still expect IceCure to lose money in the coming years, and the company has a history of missing earnings and revenue estimates, keeping fundamental concerns in focus.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ICCM. Jane Street Group LLC bought a new stake in IceCure Medical during the fourth quarter valued at approximately $67,000. Concurrent Investment Advisors LLC bought a new position in shares of IceCure Medical during the fourth quarter valued at about $48,000. Finally, Virtu Financial LLC bought a new position in IceCure Medical during the 4th quarter worth approximately $39,000. Institutional investors own 0.62% of the company’s stock.

About IceCure Medical

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.